ASDERA
- Biotech or pharma, therapeutic R&D
- Biotech – food & agriculture
ASDERA develops and outlicenses IP (pats granted) for first-in-class interventions against diseases and conditions with unmet needs and to improve health in aging by using a patented discovery platform to identify complex risk factors in genetic data others found inconclusive:
ASD-002: orphan developmental language disorder (DLD) in children at risk of autism),
ASD-004: cancer,
ASD-005: orphan pediatric LSDs (NPC, Batten, ...),
ASD-006: a co-/follow-up drug for incretin mimetics (IMs, incl GLP-1/GIP RAs) against metabolic syndrome (obesity, T2DM, NASH, ... ), neurodegeneration (AD, PD, ... orphan ALS, HD, ... ) and aging,
ASD-NP6: a version of ASD-006 for people who do not want to take an IM drug for the rest of their lives..
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}